The company's guidance aligns with expectations that 2014 will be a nail-biter.
Aggressive new recommendations for treating patients at high risk of cardiovascular disease could significantly alter the treatment landscape.
The duo whose nonprofit served as neutral ground for getting FDA and industry talking about digital marketing is starting a for-profit research and advisory firm.
What the agency writes in a recent warning letter to a dietary supplement firm is instructive with regard to "Liking" off-label posts.
Diagnostics firm MedMira gets a contract from the US Army to develop a screening tool, and the FDA proposes some new device guidelines.
The CDC's proposal that all US baby boomers get a one-time test for the hepatitis C virus has already given a boost to drugmakers in the antiviral space.
Weary of FDA foot-dragging on digital and social media guidance for pharmas, a group of 60-some industry digerati have put together guidelines of their own.
The FDA issued guidance clarifying narrow questions of scientific or generic name placement in ads and labeling in different media, including electronic media.
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.